Alendronate
ApprovedUNKNOWN 0 watching 0 views this week🔥 Hot
85
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Non-Traumatic Osteonecrosis
Conditions
Non-Traumatic Osteonecrosis
Trial Timeline
Jun 1, 2005 → Jun 1, 2008
NCT ID
NCT00265252About Alendronate
Alendronate is a approved stage product being developed by Merck for Non-Traumatic Osteonecrosis. The current trial status is unknown. This product is registered under clinical trial identifier NCT00265252. Target conditions include Non-Traumatic Osteonecrosis.
Hype Score Breakdown
Clinical
30
Activity
20
Company
10
Novelty
10
Community
12
Clinical Trials (5)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00236002 | Phase 3 | Terminated |
| NCT00265252 | Approved | UNKNOWN |
| NCT00259857 | Phase 2 | Completed |
| NCT00346190 | Phase 3 | UNKNOWN |
| NCT00010439 | Phase 2 | Completed |